作者
Takashi Imamoto, Hiroyoshi Suzuki, Takanobu Utsumi, Takumi Endo, Makoto Takano, Masashi Yano, Koji Kawamura, Naoto Kamiya, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa
发表日期
2009/9/30
来源
Future Oncology
卷号
5
期号
7
页码范围
1005-1013
出版商
Taylor & Francis
简介
Androgens are essential for prostatic growth and development, but also play a significant role in the pathogenesis of prostate disease. The traditional view that higher testosterone levels represent a risk factor for prostate cancer (PCa) appears to have little evidentiary support. Some studies have described a relationship between lower testosterone levels and more advanced disease. Serum androgen levels, within a broad range, are thus suggested to show no association with PCa risk, whereas low rather than high serum testosterone levels have been found to be associated with advanced or high-grade disease at the time of PCa diagnosis. Dihydrotestosterone, the principal prostatic androgen, is transformed from testosterone by type 1 and type 2 5α-reductase, and therapeutic benefits may thus be potentially achieved through the inhibition of 5α-reductase.
学术搜索中的文章
T Imamoto, H Suzuki, T Utsumi, T Endo, M Takano… - Future Oncology, 2009